Telix Pharmaceuticals Limited (TLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TLX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
Shares of Australia-based Telix Pharmaceuticals (TLX) rose 6% Friday as the U.S. Food and Drug Administration (FDA) approved the biopharma firm's agent for use in tests to screen for prostate cancer.
Telix Pharmaceuticals Limited (TLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Telix Pharmaceuticals Limited (TLX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.